Invex Therapeutics Receives UK approval to start phase III Presendin trial
- Invex Therapeutics (IXC) gets the tick of approval to start its phase III Presendin trial in the UK, treating patients with idiopathic intracranial hypertension (IIH)
- A total of 240 recently diagnosed IIH patients will either receive Presendin or a placebo once a week over 24 weeks in a double-blind trial
- Patients with IIH suffer from raised intracranial pressure, causing disabling daily headaches and in some instances, a compressed optic nerve
- The first patient is expected to be dosed after June 30
- IXC ends the day 4.49 per cent in the green with shares trading at 46.5 cents
